Histone Deacetylases in Renal Cell Cancer
Author Information
Author(s): Fritzsche Florian R, Weichert Wilko, Röske Annika, Gekeler Volker, Beckers Thomas, Stephan Carsten, Jung Klaus, Scholman Katharina, Denkert Carsten, Dietel Manfred, Kristiansen Glen
Primary Institution: Charité – Universitätsmedizin, Berlin, Germany
Hypothesis
What is the expression of histone deacetylases (HDAC) 1, 2, and 3 in renal cell cancer?
Conclusion
Class I HDAC isoforms 1 and 2 are highly expressed in renal cell cancer, while HDAC 3 shows low expression rates.
Supporting Evidence
- Almost 60% of renal cell carcinomas expressed HDAC isoforms 1 and 2.
- HDAC 3 was detected in only 13% of renal tumors.
- HDAC expression correlated with the proliferative activity of the tumors.
Takeaway
This study looked at how certain proteins called HDACs behave in kidney cancer. They found that two types of these proteins are very common in the cancer, while another type is not.
Methodology
The study used immunohistochemistry on tissue microarrays to analyze HDAC expression in renal cell carcinomas and normal renal tissue.
Limitations
The study did not assess the acetylation status of histones in RCC.
Participant Demographics
Patients aged 28 to 92 years, with a median age of 62; 79.3% had clear cell RCC.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website